Prevest Denpro Ltd Q2 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 19 Jul 2026 | Healthcare Equipment & Supplies | Market Cap: ₹458 Cr
Prevest DenPro expects to cross Rs. Prevest DenPro expects to cross Rs.
From Prevest Denpro Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹405
Market Cap
₹458 Cr
P/E Ratio
21.4
How does Prevest Denpro Ltd rank in Healthcare Equipment & Supplies?
Compare Prevest Denpro Ltd against every Healthcare Equipment & Supplies company this quarter on revenue, margins and earnings-call signals.
Prevest Denpro Ltd — Quarterly revenue & net profit
Revenue Net Profit
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Reported quarterly figures (₹ Cr). Latest: revenue ₹19 Cr, net profit ₹6 Cr.
Full financials →📊 Revenue & Sales Performance
- →Prevest DenPro expects to cross Rs. 100 crores in revenue within three years.
- →Current growth trajectory indicates a 15% year-on-year increase in top-line revenue.
- →For the financial year 2025-2026, an 18% cumulative growth has been achieved so far, with an anticipated 20% growth in the next half-year.
- →Domestic sales growth is expected to return to double digits following disruptions from GST changes and regional events.
- →U.S. market growth is strong, with a 43-47% increase in the first half year, expected to continue despite tariff adjustments.
- →Digital dentistry, including 3D printing solutions, disinfectants, and oral care products, is anticipated to drive significant future growth.
- →New product lines are high-margin and expected to contribute progressively.
- →Operational efficiencies and controlled expenses will support profitability as volumes grow.
📈 Profitability & Margins
- →Prevest DenPro expects to cross Rs. 100 crore in revenue within the next 3 years, growing top-line at around 15% year-on-year.
- →Profitability is anticipated to increase at a rate higher than revenue growth due to stable margins and no significant increase in operational expenses.
- →EBITDA margins are maintained around 39%, with PAT margin at approximately 27% in H1 FY26.
- →Operational efficiencies and cost controls contribute to sustainable margins and earnings growth.
- →Expansion is focused on high-margin, innovative products, particularly digital dentistry, biomaterials, and disinfectant products.
- →Growth in export markets (24% YoY in H1 FY26) and improved domestic sales post-GST realignment support earnings momentum.
- →Management expects over 20% revenue growth in H2 FY26, with continued margin maintenance.
- →Earnings Per Share (EPS) is expected to improve in line with profit growth, supported by efficient expense management and revenue expansion.
🏗️ Capital Expenditure Plans
- →No significant new capital investments or expansion plans are currently anticipated.
- →The company has already made necessary investments to support expected sales growth.
- →Future expansion will be managed within existing budget thresholds without substantial additional expense.
- →Focus is on operational efficiencies and maintaining profitability rather than increasing operational expenses.
- →New product development and commercialization efforts are ongoing but do not currently require major capital outlay.
- →Manufacturing capacity for new product lines like 3D resin is already sufficient for domestic and international demand for the next 5 years.
- →Management is maintaining financial discipline with prudent working capital management and cost control.
💰 Fundraising & Capital Structure
- →There is no mention of any current or future fundraising through debt or equity in the transcript.
- →The company emphasizes maintaining a healthy balance sheet and strong cash flows.
- →Management states that they have made investments for sales growth and do not expect further major expense or investment increases.
- →Profitability and operational expenses are being managed carefully without the need for additional funding at this time.
- →The focus is on organic growth through operational efficiencies, new product development, and market expansion rather than external fundraising.
📋 Order Book & Pipeline
The transcript provided does not explicitly mention the current or expected order book or pending orders for Prevest DenPro Limited. However, the following points are relevant insights related to demand and order flow:
- Export markets have shown strong growth with 24% increase in the first half of the financial year, indicating healthy order inflow from international customers.
- U.S. market is growing well despite recent tariff issues, with private-label contracts and initial orders through their subsidiary Axiodent.
- Domestic market saw a temporary slowdown due to external disruptions but shows recovery with double-digit growth expected in the second half.
- The launch of new products like Rotoflex endodontic files and disinfectants are seeing good acceptance, suggesting continuing demand.
- Engagements with dental associations and conferences help secure direct orders from clinics and dentists.
- Discussions with distributors in new geographies are at advanced stages, potentially leading to new orders.
No exact figures on order book or pending orders were disclosed.
Key Metrics
Frequently Asked Questions
What were Prevest Denpro Ltd Q2 FY26 results?
Prevest DenPro expects to cross Rs. Prevest DenPro expects to cross Rs.
What is Prevest Denpro Ltd share price analysis?
Prevest Denpro Ltd currently shows a neutral. The stock trades at a P/E of 21.4 with a market cap of ₹458 Cr. Investors should review the full earnings analysis for detailed insights.
Is Prevest Denpro Ltd planning capital expenditure?
No significant new capital investments or expansion plans are currently anticipated.
Keep Prevest Denpro Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.